SEC Form 4 · accession 0001437749-26-029231
PULSE BIOSCIENCES, INC. · PLSE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Liane Rae Teplitsky
Officer — Chief Operating Officer
Period of report
Apr 8, 2026
Accepted (ET)
Aug 28, 2026 · 7:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001625101
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 8, 2026 | A | 200,000 | A | — | Aug 8, 2033 | Common Stock | 200,000 | 200,000 | D |
| Stock Option (right to buy)F3 | $19.06 | Aug 8, 2026 | A | 700,000 | A | — | Aug 8, 2036 | Common Stock | 700,000 | 700,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
- F2The RSUs will vest upon certain performance-based criteria established by the Board of Directors.
- F3Two sevenths of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of three performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP product revenue targets ranging from $100 million to $330 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone.